Lung Cancer Diagnostics Market Size and Forecast 2025–2033: A Rapidly Advancing Sector Transforming Early Detection

Lung cancer continues to be one of the world’s most challenging and life-threatening diseases, claiming more lives annually than any other cancer type. As early detection becomes increasingly critical in improving survival rates, the global lung cancer diagnostics market is undergoing a major transformation fueled by technological innovation, expanding awareness, and growing investments in screening infrastructure.

According to Renub Research, the Lung Cancer Diagnostics Market is projected to grow from US$ 20.28 billion in 2024 to US$ 38.00 billion by 2033, expanding at a CAGR of 7.23% between 2025 and 2033. The market’s growth is being supported by heightened public accessibility to diagnostic facilities, an increase in ambulance and emergency services, and rising incidences of severe health conditions—particularly chronic respiratory diseases and cardiac disorders.

As governments, healthcare leaders, and diagnostic innovators accelerate efforts toward faster, more accurate, and more accessible cancer detection, the lung cancer diagnostics landscape is poised for a decade of substantial evolution.

Download Free Sample Report

What Is Driving Growth in the Lung Cancer Diagnostics Market?

1. Rising Global Burden of Lung Cancer

Lung cancer originates when abnormal cells proliferate uncontrollably within the lung tissue. While tumors can form in any part of the lung, they frequently start in the bronchi and bronchioles—hence the term “bronchogenic carcinoma.” Alarmingly:

90% of lung cancers are linked to tobacco consumption.

Environmental pollution, occupational hazards, and genetic susceptibility are additional contributors.

Symptoms such as chronic coughing, chest pain, dysphagia, headaches, and hemoptysis often appear only at advanced stages—making early detection essential yet challenging.

The rising worldwide incidence of lung cancer is therefore a critical catalyst for the expansion of the diagnostics market.

2. Increasing Awareness About Screening and Early Detection

Public education campaigns, national screening programs, and advocacy by global health organizations are strengthening awareness around lung cancer risk factors and the importance of timely diagnosis.

A notable development is the October 2024 initiative by the Florida Lung Health Coalition and DELFI Diagnostics, supported by RadNet, Inc. and the American Lung Association. This groundbreaking program aims to revolutionize lung cancer screening and improve patient outcomes in high-risk populations.

As more individuals proactively pursue preventive checkups, demand for advanced diagnostic tools rises in parallel.

3. Breakthroughs in Diagnostic Technologies

A major force reshaping the market is the rapid progress in diagnostic technologies, including:

• Liquid Biopsy

A non-invasive blood test capable of detecting:

Tumor DNA fragments

Molecular mutations

Biomarkers linked to lung cancer

It offers faster results, lower risk, and better patient compliance compared to traditional tissue biopsy.

• Next-Generation Sequencing (NGS)

NGS enables analysis of multiple genetic mutations simultaneously, helping:

Identify tumor profiles

Guide personalized treatment

Improve precision oncology outcomes

• Advanced Imaging Systems

PET scans, CT scans, and MRI technologies have seen major upgrades in image clarity, speed, and diagnostic accuracy.

These innovations allow clinicians to detect smaller tumors earlier while reducing false positives—a crucial factor in improving survival rates.

Challenges Facing the Lung Cancer Diagnostics Market

Even with impressive advancements, several challenges impede market growth:

1. High Cost of Advanced Diagnostic Technologies

Most emerging diagnostic tools—like NGS, liquid biopsy, and PET/CT scans—are expensive to develop, maintain, and operate. This leads to:

Limited adoption in low- and middle-income countries

Higher patient out-of-pocket expenses

Slower integration into public healthcare systems

Affordability remains a pressing concern that must be addressed for global market expansion.

2. Limited Access to Screening Programs

Many regions still lack the infrastructure, funding, or healthcare personnel to implement large-scale screening initiatives. Awareness remains low in several countries, leading to late-stage diagnosis, which drastically increases mortality rates.

A combination of public health investment, training, and education is required to close these gaps.

Market Insights by Key Segments

1. Diagnosis Test Type

Imaging Tests lead the market due to their indispensable role in early tumor detection and staging.

Breakdown:

Imaging Test

Biopsy

Sputum Cytology

Molecular Test

Others

CT, MRI, and PET imaging remain essential for diagnosis, monitoring progression, and planning treatment pathways. With continuous technological improvements, imaging will remain the largest and most mature segment.

2. Cancer Type

Non-Small Cell Lung Cancer (NSCLC) dominates the diagnostics landscape. This is attributed to:

High prevalence (accounts for 85% of all lung cancers)

Multiple subtypes requiring specific diagnostic testing

Increasing adoption of targeted therapies and immunotherapies

Small Cell Lung Cancer (SCLC) remains a smaller segment but demands rapid diagnosis due to its aggressive nature.

3. End-User Industry

Hospital-Associated Laboratories hold the largest market share. Their advantages include:

Accessibility

Quicker turnaround times

Strong clinician-lab coordination

Availability of complex imaging and molecular testing tools

Other major end-users include independent diagnostic labs, imaging centers, cancer research institutes, and specialty clinics.

Regional Analysis: Market Overview Across Key Countries

The global lung cancer diagnostics market spans 25 nations across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

United States: A Global Leader in Lung Cancer Diagnostics

The U.S. remains the largest and most technologically advanced market. Key factors include:

High lung cancer incidence

Strong healthcare infrastructure

Broad adoption of advanced imaging and molecular diagnostics

Government-sponsored screening programs

In January 2023, Agilent Technologies and Quest Diagnostics partnered to expand access to the Resolution ctDx FIRST test, supporting precision diagnostics for advanced NSCLC.

Challenges include high diagnostic costs and unequal access in rural and underserved communities, but innovation continues driving strong market growth.

Germany: A Technologically Progressive European Market

Germany benefits from:

A robust healthcare system

Rapid adoption of NGS and liquid biopsy

Comprehensive cancer screening initiatives

Rising smoking rates and aging demographics continue to push demand for early detection solutions.

China: The Fastest-Growing Asian Market

China faces one of the world’s highest lung cancer burdens due to:

Pollution levels

Smoking prevalence

Large aging population

Urban areas are transforming rapidly with widespread adoption of CT and PET imaging, while government programs aim to expand awareness and screening. However, disparities in rural healthcare access remain a challenge.

Saudi Arabia: A Market Advancing Through Healthcare Modernization

Saudi Arabia’s market growth is driven by:

Rising cancer incidence

Investments under Vision 2030

Adoption of high-precision imaging and molecular diagnostics

National awareness programs

Infrastructure expansion, especially outside major cities, will be key to future growth.

Key Market Segmentation Summary

Diagnosis Test Type

Imaging Test

Biopsy

Sputum Cytology

Molecular Test

Others

Cancer Type

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

End-User

Hospital Associated Labs

Independent Diagnostic Laboratories

Diagnostic Imaging Centers

Cancer Research Institutes

Others

Countries Covered (25 Total)

North America (US, Canada), Europe (8 nations), Asia Pacific (10 nations), Latin America (3 nations), Middle East & Africa (3 nations)

Company Profiles: Leading Players in Lung Cancer Diagnostics

Illumina

Abbott Laboratories

Thermo Fisher Scientific, Inc.

QIAGEN N.V.

Roche Holding AG

Sanofi S.A.

Agilent Technologies

bioMérieux

These companies are driving advancements in NGS platforms, biomarker assays, imaging technology, and early detection solutions—paving the way for personalized medicine and improved survival outcomes.

Final Thoughts: A Market Poised for Transformational Growth

The global lung cancer diagnostics market is entering a pivotal era. Driven by innovative diagnostic technologies, rising global awareness, and sustained government investment, the sector is poised to deliver unprecedented improvements in early detection and patient management.

Still, important challenges—particularly cost barriers and limited screening infrastructure in developing nations—must be addressed to unlock the market’s full potential. As more healthcare systems adopt advanced technologies and expand screening access, early detection rates will rise, improving survival outcomes worldwide.

By 2033, with a projected valuation of US$ 38.00 billion, the lung cancer diagnostics market will not only grow in size but also redefine how the world approaches cancer detection, precision medicine, and patient care.